-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, M5lZW6jNwpZJaLsmEcvo+J+CPXoNkamuvfVPCExfvFkknY1h+dq7WYry4GZ/CdoQ 6puvfLtdN+ZRqp68TB6gnw== 0001104659-05-006185.txt : 20050214 0001104659-05-006185.hdr.sgml : 20050214 20050214130542 ACCESSION NUMBER: 0001104659-05-006185 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050214 DATE AS OF CHANGE: 20050214 GROUP MEMBERS: CITADEL DERIVATIVES LLC GROUP MEMBERS: CITADEL EQUITY FUND LTD. GROUP MEMBERS: CITADEL INVESTMENT GROUP, L.L.C. GROUP MEMBERS: CITADEL KENSINGTON GLOBAL STRATEGIES FUND LTD. GROUP MEMBERS: CITADEL WELLINGTON LLC GROUP MEMBERS: KENNETH GRIFFIN SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1204 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-37954 FILM NUMBER: 05606303 BUSINESS ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CITADEL L P CENTRAL INDEX KEY: 0001027745 IRS NUMBER: 364111741 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 131 S. DEARBORN STREET, 32ND FLOOR CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 3123952100 MAIL ADDRESS: STREET 1: 131 S. DEARBORN STREET, 32ND FLOOR CITY: CHICAGO STATE: IL ZIP: 60603 SC 13G/A 1 a05-2886_4sc13ga.htm SC 13G/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

SCHEDULE 13G

(Rule 13d-102)

 

Information Statement Pursuant to Rules 13d-1 and 13d-2

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

 

 

OSI Pharmaceuticals, Inc.

 

 

(Name of Issuer)

 

 

 

 

 

Common Stock

 

 

(Title of Class of Securities)

 

 

 

 

 

 

 

 

 

671040103

 

 

 

(CUSIP Number)

 

 

 

 

 

 

 

 

 

December 31, 2004

 

 

 

Date of Event Which Requires Filing of the Statement

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[   ]                               Rule 13d-1(b)
[X]                               Rule 13d-1(c)
[   ]                               Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Page 1 of 15



 

CUSIP NO. 671040103

13G

Page 2 of 15 Pages

 

 

1.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Limited Partnership

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)

ý

 

 

(b)

o

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois limited partnership

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

5.

SOLE VOTING POWER
0

6.

SHARED VOTING POWER

894,040 shares of Common Stock

521,852 Call Options (exercisable for 2,685,200 shares of Common Stock)

7.

SOLE DISPOSITIVE POWER
0

8.

SHARED DISPOSITIVE POWER
See Row 6 above.

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

 

CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 7.1% as of December 31, 2004 (based on 50,634,509 shares of Common Stock issued and outstanding as of December 1, 2004).

12.

TYPE OF REPORTING PERSON

 

PN; HC

 

Page 2 of 15



 

CUSIP NO. 671040103

13G

Page 3 of 15 Pages

 

 

1.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Investment Group, L.L.C.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)

ý

 

 

(b)

o

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware limited liability company

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

5.

SOLE VOTING POWER
0

6.

SHARED VOTING POWER

894,040 shares of Common Stock

521,852 Call Options (exercisable for 2,685,200 shares of Common Stock)

7.

SOLE DISPOSITIVE POWER
0

8.

SHARED DISPOSITIVE POWER
See Row 6 above.

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

 

CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 7.1% as of December 31, 2004 (based on 50,634,509 shares of Common Stock issued and outstanding as of December 1, 2004).

12.

TYPE OF REPORTING PERSON

 

OO; HC

 

Page 3 of 15



 

CUSIP NO. 671040103

13G

Page 4 of 15 Pages

 

 

1.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Kenneth Griffin

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)

ý

 

 

(b)

o

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

5.

SOLE VOTING POWER
0

6.

SHARED VOTING POWER

894,040 shares of Common Stock

521,852 Call Options (exercisable for 2,685,200 shares of Common Stock)

7.

SOLE DISPOSITIVE POWER
0

8.

SHARED DISPOSITIVE POWER
See Row 6 above.

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

 

CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 7.1% as of December 31, 2004 (based on 50,634,509 shares of Common Stock issued and outstanding as of December 1, 2004).

12.

TYPE OF REPORTING PERSON

 

IN; HC

 

Page 4 of 15



 

CUSIP NO. 671040103

13G

Page 5 of 15 Pages

 

 

1.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Wellington LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)

ý

 

 

(b)

o

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware limited liability company

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

5.

SOLE VOTING POWER
0

6.

SHARED VOTING POWER

894,040 shares of Common Stock

521,852 Call Options (exercisable for 2,685,200 shares of Common Stock)

7.

SOLE DISPOSITIVE POWER
0

8.

SHARED DISPOSITIVE POWER
See Row 6 above.

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

 

CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 7.1% as of December 31, 2004 (based on 50,634,509 shares of Common Stock issued and outstanding as of December 1, 2004).

12.

TYPE OF REPORTING PERSON

 

OO; HC

 

Page 5 of 15



 

CUSIP NO. 671040103

13G

Page 6 of 15 Pages

 

 

1.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Kensington Global Strategies Fund Ltd.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)

ý

 

 

(b)

o

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda company

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

5.

SOLE VOTING POWER
0

6.

SHARED VOTING POWER

894,040 shares of Common Stock

521,852 Call Options (exercisable for 2,685,200 shares of Common Stock)

7.

SOLE DISPOSITIVE POWER
0

8.

SHARED DISPOSITIVE POWER
See Row 6 above.

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

 

CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 7.1% as of December 31, 2004 (based on 50,634,509 shares of Common Stock issued and outstanding as of December 1, 2004).

12.

TYPE OF REPORTING PERSON

 

CO; HC

 

Page 6 of 15



 

CUSIP NO. 671040103

13G

Page 7 of 15 Pages

 

 

1.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Equity Fund Ltd.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)

ý

 

 

(b)

o

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands company

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

5.

SOLE VOTING POWER
0

6.

SHARED VOTING POWER

894,040 shares of Common Stock

521,852 Call Options (exercisable for 2,685,200 shares of Common Stock)

7.

SOLE DISPOSITIVE POWER
0

8.

SHARED DISPOSITIVE POWER
See Row 6 above.

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

 

CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 7.1% as of December 31, 2004 (based on 50,634,509 shares of Common Stock issued and outstanding as of December 1, 2004).

12.

TYPE OF REPORTING PERSON

 

CO

 

Page 7 of 15



 

CUSIP NO. 671040103

13G

Page 8 of 15 Pages

 

 

1.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Derivatives Group LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)

ý

 

 

(b)

o

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware limited liability company

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

5.

SOLE VOTING POWER
0

6.

SHARED VOTING POWER

894,040 shares of Common Stock

521,852 Call Options (exercisable for 2,685,200 shares of Common Stock)

7.

SOLE DISPOSITIVE POWER
0

8.

SHARED DISPOSITIVE POWER
See Row 6 above.

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

 

CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 7.1% as of December 31, 2004 (based on 50,634,509 shares of Common Stock issued and outstanding as of December 1, 2004).

12.

TYPE OF REPORTING PERSON

 

OO; BD

 

Page 8 of 15

 



 

 

CUSIP NO. 671040103

13G

Page 9 of 15 Pages

 

 

Item 1(a)

Name of Issuer:

OSI PHARMACEUTICALS, INC.

 

 

 

1(b)

Address of Issuer’s Principal Executive Offices:

 

 

 

 

 

58 South Service Road

 

 

Melville, New York 11747

 

 

 

Item 2(a)

Name of Person Filing

Item 2(b)

Address of Principal Business Office

Item 2(c)

Citizenship

 

 

 

Citadel Limited Partnership

 

 

131 S. Dearborn Street

 

 

32nd Floor

 

 

Chicago, Illinois 60603

 

 

Illinois limited partnership

 

 

 

 

 

Citadel Investment Group, L.L.C.

 

 

131 S. Dearborn Street

 

 

32nd Floor

 

 

Chicago, Illinois 60603

 

 

Delaware limited liability company

 

 

 

 

 

Kenneth Griffin

 

 

131 S. Dearborn Street

 

 

32nd Floor

 

 

Chicago, Illinois 60603

 

 

U.S. Citizen

 

 

 

 

 

Citadel Wellington LLC

 

 

c/o Citadel Investment Group, L.L.C.

 

 

131 S. Dearborn Street

 

 

32nd Floor

 

 

Chicago, Illinois 60603

 

 

Delaware limited liability company

 

 

Page 9 of 15



 

 

CUSIP NO. 671040103

13G

Page 10 of 15 Pages

 

 

 

 

 

 

 

Citadel Kensington Global Strategies Fund Ltd.

 

 

c/o Citadel Investment Group, L.L.C.

 

 

131 S. Dearborn Street

 

 

32nd Floor

 

 

Chicago, Illinois 60603

 

 

Bermuda company

 

 

 

 

 

Citadel Equity Fund Ltd.

 

 

c/o Citadel Investment Group, L.L.C.

 

 

131 S. Dearborn Street

 

 

32nd Floor

 

 

Chicago, Illinois 60603

 

 

Cayman Islands company

 

 

 

 

 

Citadel Derivatives Group LLC

 

 

c/o Citadel Investment Group, L.L.C.

 

 

131 S. Dearborn Street

 

 

32nd Floor

 

 

Chicago, Illinois 60603

 

 

Delaware limited liability company

 

2(d)

Title of Class of Securities:

 

 

 

Common Stock, par value $0.01 per share

 

 

2(e)

CUSIP Number:               671040103

 

 

Item 3

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

Page 10 of 15



 

CUSIP NO. 671040103

13G

Page 11 of 15 Pages

 

 

 

(a)

[__]

Broker or dealer registered under Section 15 of the Exchange Act;

 

 

 

 

 

(b)

[__]

Bank as defined in Section 3(a)(6) of the Exchange Act;

 

 

 

 

 

(c)

[__]

Insurance company as defined in Section 3(a)(19) of the Exchange Act;

 

 

 

 

 

(d)

[__]

Investment company registered under Section 8 of the Investment Company Act;

 

 

 

 

 

(e)

[__]

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 

 

 

 

 

(f)

[__]

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

 

 

 

 

 

(g)

[__]

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 

 

 

 

 

(h)

[__]

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

 

 

 

 

(i)

[__]

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

 

 

 

 

(j)

[__]

Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

 

If this statement is filed pursuant to Rule 13d-1(c), check this box.  ý

 

Item 4

Ownership:

 

CITADEL LIMITED PARTNERSHIP
CITADEL INVESTMENT GROUP, L.L.C.
KENNETH GRIFFIN
CITADEL WELLINGTON LLC
CITADEL KENSINGTON GLOBAL STRATEGIES FUND LTD.
CITADEL EQUITY FUND LTD.
CITADEL DERIVATIVES GROUP LLC

 

Page 11 of 15



 

CUSIP NO. 671040103

13G

Page 12 of 15 Pages

 

 

(a)

Amount beneficially owned:

 

 

894,040 shares of Common Stock

 

521,852 Call Options (exercisable for 2,685,200 shares of Common Stock)

 

 

(b)

Percent of Class:

 

 

Approximately 7.1% as of December 31, 2004 (based on 50,634,509 shares of Common Stock issued and outstanding as of December 1, 2004).

 

 

(c)

Number of shares as to which such person has:

 

 

 

(i)

sole power to vote or to direct the vote:

 

 

 

 

 

0

 

 

 

 

(ii)

shared power to vote or to direct the vote:

 

 

 

 

 

See Item 4(a) above.

 

 

 

 

(iii)

sole power to dispose or to direct the disposition of:

 

 

 

 

 

0

 

 

 

 

(iv)

shared power to dispose or to direct the disposition of:

 

 

 

 

 

See Item 4(a) above.

 

 

 

Item 5

Ownership of Five Percent or Less of a Class:

 

 

Not Applicable.

 

 

 

Item 6

Ownership of More than Five Percent on Behalf of Another Person:

 

 

Not Applicable.

 

 

 

Item 7

Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

 

 

See Item 2 above.

 

 

 

Item 8

Identification and Classification of Members of the Group:

 

 

Not Applicable.

 

 

 

Item 9

Notice of Dissolution of Group:

 

 

Not Applicable.

 

Page 12 of 15



 

CUSIP NO. 671040103

13G

Page 13 of 15 Pages

 

 

Item 10

Certification:

 

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

This Schedule 13G/A is being filed solely to make certain corrective changes to the Reporting Persons party to the Schedule 13G/A filed on February 9, 2005, reflecting internal organization changes made within the reporting group on or prior to
December 31, 2004.

 

* Mathew B. Hinerfeld is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission on February 4, 2005, and hereby incorporated by reference herein.  The power of attorney was filed as an attachment to a filing by Citadel Limited Partnership on Schedule 13G/A for Komag, Incorporated.

 

Page 13 of 15



 

CUSIP NO. 671040103

13G

Page 14 of 15 Pages

 

 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated this 14h day of February, 2005

 

 

 

 

 

KENNETH GRIFFIN

 

 

 

 

CITADEL LIMITED PARTNERSHIP

 

By:

/s/ Matthew B. Hinerfeld

 

 

 

 

Matthew B. Hinerfeld, attorney-in-fact*

By:

 Citadel Investments Group L.L.C.

 

 

 

 

Its General Partner

 

 

 

 

 

CITADEL INVESTMENT GROUP, L.L.C.

 

 

 

 

 

By:

/s/ Matthew B. Hinerfeld

 

By:

/s/ Matthew B. Hinerfeld

 

Matthew B. Hinerfeld, Managing

 

 

Matthew B. Hinerfeld, Managing

 

Director and Deputy General Counsel

 

 

Director and Deputy General Counsel

 

 

 

 

 

 

 

 

 

 

 

 

CITADEL DERIVATIVES GROUP LLC

 

 

 

 

 

 

 

 

By:

Citadel Limited Partnership,

 

 

 

 

its Managing Member

 

 

 

 

 

 

 

 

By:

Citadel Investments Group L.L.C.,

 

 

 

 

its General Partner

 

 

 

 

 

 

 

 

By:

/s/ Matthew B. Hinerfeld

 

 

 

 

Mathew B. Hinerfeld, Managing

 

 

 

 

Director and Deputy General Counsel

 

 

 

 

 

 

 

 

 

 

 

 

CITADEL EQUITY FUND LTD.

 

 

 

 

 

 

 

 

By:

Citadel Limited Partnership,

 

 

 

 

its Portfolio Manager

 

 

 

 

 

 

 

 

By:

Citadel Investments Group, L.L.C.

 

 

 

 

its General Partner

 

 

 

 

 

 

 

 

By:

/s/ Matthew B. Hinerfeld

 

 

 

 

Matthew B. Hinerfeld, Managing

 

 

 

 

Director and Deputy General Counsel

 

 

Page 14 of 15



 

CUSIP NO. 671040103

13G

Page 15 of 15 Pages

 

 

CITADEL WELLINGTON LLC

 

CITADEL KENSINGTON GLOBAL
STRATEGIES FUND LTD.

 

 

 

 

By:

Citadel Limited Partnership,
its Managing Member

 

By:

Citadel Limited Partnership,
its Portfolio Manager

 

 

 

 

 

By:

Citadel Investment Group, L.L.C.,
its General Partner

 

By:

Citadel Investment Group, L.L.C.,
its General Partner

 

 

 

 

 

By:

/s/ Matthew B. Hinerfeld

 

 

By:

/s/ Matthew B. Hinerfeld

 

 

Matthew B. Hinerfeld, Managing

 

 

Matthew B. Hinerfeld, Managing

 

Director and Deputy General Counsel

 

 

Director and Deputy General Counsel

 

 

 

 

Page 15 of 15


 

-----END PRIVACY-ENHANCED MESSAGE-----